Abstract
An activation of pro–inflammatory cytokines in the central nervous system is associated with cognitive disturbances. This process is mediated by prostaglandins and cyclo–oxygenase–2 (COX–2). COX–2 inhibitors have been suggested to show beneficial effects in disorders associated with cognitive disturbance, although clinical effects on cognition have not been shown until today. Data from a schizophrenia study were reevaluated under the aspect whether an effect on the positive and negative syndrome scale (PANSS) factor cognition can be observed during therapy with the COX–2 inhibitor celecoxib add on to risperidone in comparison to riperidone alone. Beside the effect on the PANSS total score, the effect on the cognition factor was the most pronounced using the analysis of covariance compared to all other factors of the PANSS (p <0.06). Although suggestions of basic research led to an expected therapeutic effect of COX–2 inhibitors on cognition, this effect could not yet be shown clinically. In schizophrenia, the effect on cognition contributes to the therapeutic effect of COX–2 inhibitors.
Similar content being viewed by others
References
Aisen PS, Schafer KA, Grundman M, et al. (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289:2819–2826
Andreasson KI, Savonenko A, Vidensky S, et al. (2001) Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J Neurosci 21:8198–8209
Bliss TVP, Collingridge GI (1993) A synaptic model of memory: Long term potentiation in the hippocampus. Nature 361:31–39
Breder CD, Saper CB (1996) Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide. Brain Res 713:64–69
Collantes-Esteves E, Fernandez-Perrez Ch (2003) Improved selfcontrol of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.Curr Med Res Opin 19:402–410
Dickerson FB,Boronow JJ, Stallings C, et al. (2003) Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch Gen Psychiatry 60:466–472
Giovannini MG, Scali C, Prosperi C, et al. (2002) Beta-amyloidinduced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis 11:257–274
Kaufmann WE,Worley PF, Pegg J, et al. (1996) COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 93:2317–2321
Kraepelin E (1899) Psychiatrie. Ein Lehrbuch für Studierende und Ärzte, 6.Auflage. Barth, Leipzig
Launer LJ (2003) Non-steroidal anti-inflammatory drugs and Alzheimer’s disease: what next? JAMA 289:2865–2867
Lindenmayer JP, Bernstein-Hyman R, Grochowski S (1994) A new five factor model of schizophrenia. Psychiatr Q 65:299–322
Malenka RC (1994) Synaptic plasticity in the hippocampus: LTP and LTD. Cell 78:535–538
McGeer PL (2000) Cyclo-oxygenase-2 inhibitors. Rationale and therapeutic potential for Alzheimer’s disease. Drugs Aging 1:1–11
Müller N, Riedel M, Scheppach C, et al. (2002) Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 159: 1029–1034
Murray HJ, O’Connor JJ (2003) A role for COX-2 and p38 mitogen activated protein kinase in long-term depression in the rat dentate gyrus in vitro. Neuropharmacology 44:374–380
Scali C, Giovannini MG,Prosperi C, et al. (2003) The selective cyclooxygenase- 2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience 117:909–919
Teunissen CE, van Boxtel MP, Bosma H, et al. (2003) Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol 134:142–150
Yamagata K, Andreasson KI, Kaufmann WI, et al. (1993) Expression of mitogen-inducable cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 11:371–386
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Müller, N., Riedel, M., Schwarz, M.J. et al. Clinical effects of COX–2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 255, 149–151 (2005). https://doi.org/10.1007/s00406-004-0548-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00406-004-0548-4